Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
9 May 24
8-K
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
8 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Departure of Directors or Certain Officers
4 Apr 24
S-3ASR
Automatic shelf registration
19 Mar 24
8-K
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
19 Mar 24
8-K
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
12 Mar 24
D
$350.00 mm in equity, sold $350.00 mm, 36 investors
11 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Mar 24
8-K
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
1 Mar 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
28 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
18 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 23
S-8
Registration of securities for employees
7 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
13 Sep 23
424B5
Prospectus supplement for primary offering
13 Sep 23
424B5
Prospectus supplement for primary offering
11 Sep 23
8-K
Regulation FD Disclosure
11 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
UPLOAD
Letter from SEC
4 Apr 23
CORRESP
Correspondence with SEC
15 Mar 23
8-K
Other Events
13 Mar 23
S-8
Registration of securities for employees
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
28 Feb 23
Latest ownership filings
144
Notice of proposed sale of securities
8 May 24
4
Richard Scott Struthers
22 Apr 24
4
Dana Pizzuti
17 Apr 24
4
Richard Scott Struthers
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Richard Scott Struthers
8 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Stephanie Okey
2 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Jeff E. Knight
26 Mar 24
4
Dana Pizzuti
22 Mar 24
4
Matthew K Fust
22 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
4
Dana Pizzuti
20 Mar 24
4
Jeff E. Knight
20 Mar 24
4
James Hassard
20 Mar 24
4
Stephen F. Betz
20 Mar 24
4
Marc Wilson
20 Mar 24
4
Richard Scott Struthers
20 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
SC 13G
EcoR1 Capital, LLC
11 Mar 24
4
James Hassard
6 Mar 24
4
Marc Wilson
6 Mar 24
4
Richard Scott Struthers
6 Mar 24
4
Dana Pizzuti
6 Mar 24
4
Jeff E. Knight
6 Mar 24
4
Stephen F. Betz
6 Mar 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
1 Mar 24
144
Notice of proposed sale of securities
28 Feb 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
4
Richard Scott Struthers
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
BRAIDWELL LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
DRIEHAUS CAPITAL MANAGEMENT LLC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
5
Jeff E. Knight
12 Feb 24